Research Examines Efficacy Of Sglt2 Inhibitor As 2ndline Diabetes Therapy | Latest News RSS feed
Research Examines Efficacy Of Sglt2 Inhibitor As 2ndline Diabetes Therapy - Latest News
Research examines efficacy of SGLT-2 inhibitor as 2nd-line diabetes therapy
Researchers used a cohort of 9,097 adults with type 2 diabetes and found that more than one-third of those who took SGLT-2 inhibitors as a second-line therapy to metformin experienced an HbA1C reducti... read more
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
Dapagliflozin, a selective SGLT2 inhibitor, has previously been shown to induce ... was conducted at five sites in the United States: Orlando Clinical Research Center, Orlando, FL; Diabetes and Glandu... read more
A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
In contrast, SGLT2 ... inhibitor tofogliflozin significantly increased food intake in rats. 32 Previous studies have shown that SGLT2 expression in urinary exfoliated proximal tubular cells was signif... read more
Looking for another news?
Buy vTv Therapeutics For Its Novel Alzheimer's And Anti-Diabetic Drug Candidates.
Extensive research has now shown that dysfunction of the GK enzyme may lead to development of type II diabetes. In preclinical studies, drugs targeting the activation of GK enzyme have shown efficacy ... read more
Diabetes And Upcoming REWIND Data Key Topics Of Debate For Eli Lilly
Diabetes growth should be driven by Trulicity and Jardiance, although both face upcoming competition from Novo Nordisk's oral semaglutide. Trulicity also faces competition from Ozempic that has shown ... read more
AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76 th Scientific Sessions
The studies to be presented evaluate the management of multiple risk factors associated with type 2 diabetes ... SGLT-2 inhibitors, GLP-1 receptor agonists and DPP-4 inhibitors. As a strategic therapy ... read more